WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013049263) SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2013/049263    International Application No.:    PCT/US2012/057406
Publication Date: 04.04.2013 International Filing Date: 27.09.2012
IPC:
C07D 495/04 (2006.01), C07D 498/04 (2006.01), A61P 35/00 (2006.01), A61K 31/424 (2006.01), A61K 31/505 (2006.01)
Applicants: BRISTOL-MYERS SQUIBB COMPANY [US/US]; Route 206 and Province Line Road Princeton, New Jersey 08543-4000 (US)
Inventors: BALOG, James Aaron; (US).
HUANG, Audris; (US).
VELAPARTHI, Upender; (US).
LIU, Peiying; (US)
Agent: GREENBLATT, Gary D.; Bristol-Myers Squibb Company P.O. Box 4000 Princeton, New Jersey 08543-4000 (US)
Priority Data:
61/539,570 27.09.2011 US
Title (EN) SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS
(FR) COMPOSÉS D'HÉTÉROARYLE BICYCLIQUES SUBSTITUÉS
Abstract: front page image
(EN)Disclosed are azaindazole compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: X is O and Y is N; or X is S and Y is CH; Z is CR2 or N; Q is a heteroaryl; and R1 is defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
(FR)La présente invention concerne des composés d'azaindazole de formule (I), ou un de leurs sels pharmaceutiquement acceptables. Dans la formule, X représente O et Y représente N ; ou X représente S et Y représente CH ; Z représente CR2 ou N ; Q représente un hétéroaryle ; et R1 est défini ici. L'invention concerne également des méthodes d'utilisation de tels composés dans le traitement d'au moins un état pathologique associé à CYP17 tel que, par exemple, un cancer, et des compositions pharmaceutiques comprenant de tels composés.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)